Eisai And Daiichi Sankyo To Strengthen In-house R&D Capabilities
This article was originally published in PharmAsia News
Executive Summary
To strengthen research and development capability, Eisai will establish quasi-venture enterprise units inside the company. The units will conduct new drug discovery and product commercialization. The move is aimed to reorganize the company's domestic and overseas research staff in oncology and other areas and speed up new drug development. Along the same lines, Daiichi Sankyo will utilize Ranbaxy's research facilities and expand its R&D capabilities. (Click here for more - Japanese language